KR20190139053A - A drug for treating shoulder periarthritis and its preparation method - Google Patents
A drug for treating shoulder periarthritis and its preparation method Download PDFInfo
- Publication number
- KR20190139053A KR20190139053A KR1020180065567A KR20180065567A KR20190139053A KR 20190139053 A KR20190139053 A KR 20190139053A KR 1020180065567 A KR1020180065567 A KR 1020180065567A KR 20180065567 A KR20180065567 A KR 20180065567A KR 20190139053 A KR20190139053 A KR 20190139053A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- drug
- periarthritis
- shoulder
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 229940079593 drug Drugs 0.000 title claims abstract description 55
- 206010034464 Periarthritis Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 241000283074 Equus asinus Species 0.000 claims description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims description 6
- 210000001364 upper extremity Anatomy 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000002662 enteric coated tablet Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000007919 dispersible tablet Substances 0.000 claims description 4
- 239000008298 dragée Substances 0.000 claims description 4
- 239000007941 film coated tablet Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000007940 sugar coated tablet Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 235000014101 wine Nutrition 0.000 claims description 3
- -1 decoctions Substances 0.000 claims description 2
- 210000001156 gastric mucosa Anatomy 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 239000002826 coolant Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241001233061 earthworms Species 0.000 abstract description 4
- 240000000691 Houttuynia cordata Species 0.000 abstract description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract description 3
- 241000737253 Lygodium japonicum Species 0.000 abstract description 2
- 240000001810 Angelica gigas Species 0.000 abstract 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract 1
- 244000215554 Nepeta hederacea Species 0.000 abstract 1
- 235000011755 Nepeta hederacea Nutrition 0.000 abstract 1
- 239000006072 paste Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 239000003826 tablet Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 240000002045 Guettarda speciosa Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000000323 shoulder joint Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 241000220436 Abrus Species 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036448 vitalisation Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
본 발명은 약물 분야에 관한 것으로서, 특히 어깨 관절 주위염 치료용 약물 및 이의 제조방법에 관한 것이다.TECHNICAL FIELD The present invention relates to the field of drugs, and more particularly, to a drug for treating periarthritis of the shoulder and a preparation method thereof.
어깨 관절 주위염은 어깨 관절 주위의 근육, 힘줄, 점액낭 및 관절낭과 같은 부드러운 조직에의 만성의 무균성 염증이다. 염증은 관절 안팎에서 유착을 일으켜 어깨 관절의 활동에 영향을 준다. 어깨 관절 주위염 병변은 넓은 범위의 통증, 광범위한 기능 제한 및 넓은 범위의 압통을 특징으로 한다. 오십견(동결견)의 전체 이름은 견갑상완 관절 주위염으로, 중국 전통 의학 분야에서는 어깨 주위의 힘줄과 혈관에 풍한습의 침입으로 인한 만성 질환으로 믿어지고 있다. 영기와 위기간 부조화 및 인체의 뼈와 근육의 약화로 인해, 외래 병원성 인자는 어깨 주위의 힘줄과 혈관에 침투하여 손상시키고, 기와 혈의 막힘으로 인한 고통을 야기한다.Periarthritis of the shoulder is chronic, aseptic inflammation of the soft tissues such as muscles, tendons, bursa, and articular capsules around the shoulder joint. Inflammation causes adhesions inside and outside the joints that affect the activity of the shoulder joints. Shoulder arthroscopic lesions are characterized by a wide range of pain, a wide range of functional limitations, and a wide range of tenderness. The full name of the dog is called scapula periarthritis. In traditional Chinese medicine, it is believed to be a chronic disease caused by invasion of tendons and blood vessels around the shoulders. Due to reiki and gastric insufficiency and weakening of the bones and muscles of the human body, foreign pathogenic factors penetrate and damage tendons and blood vessels around the shoulder, causing pain due to blockage of the Gi and blood.
현재, 어깨 관절 주위염 치료 약물들은 약간의 완화 효과를 내지만, 약한 표적성, 긴 치료주기 및 큰 부작용의 결함들이 있다. 따라서, 상기 결함들을 극복하기 위해 어깨 관절 주위염 치료를 위한 신약에의 긴급한 필요가 있다.Currently, the treatment of periarthritis shoulder shoulders has a mild alleviating effect, but has weak targets, long treatment cycles and major side effects. Thus, there is an urgent need for new drugs for the treatment of periarthritis of the shoulder to overcome these deficiencies.
상기 문제의 관점에서, 본 발명은 상기 문제점들 또는 적어도 상기 문제점들의 일부를 해결할 수 있는 어깨 관절 주위염 치료 약물을 제공하고, 이는 종래의 약물들의 열악한 치료 효과의 결함들을 극복하기 위해 사용된다.In view of the above problem, the present invention provides a shoulder arthritis therapeutic drug that can solve the problems or at least some of the problems, which is used to overcome the deficiencies of the poor therapeutic effect of conventional drugs.
제 1양태에 따르면, 본 발명은 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부 및 당귀 5 내지 15 중량부를 포함하는 어깨 관절 주위염 치료용 약물을 제공한다.According to the first aspect, the present invention is for the treatment of periarthritis of the shoulder, including 5 to 18 parts by weight, 10 to 25 parts by weight of fern, 13 to 20 parts by weight, worms 12 to 20 parts by weight, and 5 to 15 parts by weight of Angelica. Provide medication.
제 2양태에 따르면, 본 발명은 하기의 단계들을 포함하는, 상기 실시예 중 어느 하나에 따른 약물의 제조방법을 제공한다:According to a second aspect, the invention provides a process for the manufacture of a medicament according to any one of the above embodiments, comprising the following steps:
제 1단계로서, 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 측량하는 단계;As a first step, 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of silly fern, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworms, and 5 to 15 parts by weight of donkey
제 2단계로서, 상기 원료들을 분쇄하여 분말 혼합물을 얻는 단계;In a second step, grinding the raw materials to obtain a powder mixture;
제 3단계로서, 물에 상기 혼합물을 0.5 내지 1시간 동안 침지 후 결과물을 센 불에서 30분 동안 달여 탕약을 얻는 단계;In a third step, the mixture is immersed in water for 0.5 to 1 hour and then the resultant is decanted for 30 minutes on a high heat to obtain a decoction;
제 4단계로서, 상기 탕약을 냉각한 후 100 내지 250 메쉬 여과포로 여과하여 여과액을 얻고, 여과액을 농축하여 1.2 내지 1.25 밀도의 진한 페이스트를 얻는 단계;As a fourth step, after cooling the medicament and filtered through a 100 to 250 mesh filter cloth to obtain a filtrate, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
제 5단계로서, 상기 진한 페이스트를 건조시킨 후 건조된 결과물을 분쇄하고, 체로 걸러 표적 약물을 얻는 단계. As a fifth step, after drying the thick paste, the dried product is ground and sieved to obtain a target drug.
본 발명은 어깨 관절 주위염 치료를 위한 약물 및 그 제조방법을 개시한다. 본 발명에 따른 어깨 관절 주위염 치료 약물은 종래 약물들과 다른 구성을 갖고, 종래 약물들의 결함을 극복할 수 있다.The present invention discloses a drug for the treatment of periarthritis of the shoulder and a method of manufacturing the same. The shoulder arthritis therapeutic drug according to the present invention has a different configuration from the conventional drugs, and can overcome the deficiencies of the conventional drugs.
1. 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 포함하는 어깨 관절 주위염 치료용 약물1. Drugs for the treatment of periarthritis of the shoulder, including 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of fern, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworm, and 5 to 15 parts by weight of Angelica
2. 위 1에 있어서,2. in the above 1,
상기 약물은 위령선 20 내지 30 중량부를 더 포함하는 어깨 관절 주위염 치료용 약물The drug is a drug for the treatment of periarthritis of the shoulder further comprising 20 to 30 parts by weight gastric gland
3. 위 1에 있어서,3. In the above 1,
상기 약물은 상지 12 내지 18 중량부를 더 포함하는 어깨 관절 주위염 치료용 약물The drug is a drug for the treatment of periarthritis of the shoulder further comprising 12 to 18 parts by weight of the upper limbs
4. 위 1에 있어서,4. In the above 1,
상기 약물은 필름 코팅 정제, 당 코팅 정제, 장용 코팅 정제, 분산성 정제, 캡슐제, 과립제, 탕약제, 혼합물, 시럽, 약용 포도주, 주사제, 경구용 용액 및 경구용 현탁액 중 적어도 어느 하나의 제형인 어깨 관절 주위염 치료용 약물The drug may be in the form of at least one of film coated tablets, sugar coated tablets, enteric coated tablets, dispersible tablets, capsules, granules, medicinal preparations, mixtures, syrups, medicinal wines, injectables, oral solutions and oral suspensions. Drugs for the treatment of periarthritis of the shoulder
5. 하기의 단계들을 포함하는, 위 1 내지 4 중 어느 하나의 약물의 제조방법:5. Method of preparing a drug of any one of the above 1 to 4, comprising the following steps:
제 1단계로서, 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 무게 측정하는 단계;As a first step, 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of silcho, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworm, 5 to 15 parts by weight of donkey;
제 2단계로서, 상기 원료들을 분쇄하여 분말 혼합물을 얻는 단계;In a second step, grinding the raw materials to obtain a powder mixture;
제 3단계로서, 물에 상기 혼합물을 0.5 내지 1시간 동안 침지 후 결과물을 센 불에서 30분 동안 달여 탕약을 얻는 단계;In a third step, the mixture is immersed in water for 0.5 to 1 hour and then the resultant is decanted for 30 minutes on a high heat to obtain a decoction;
제 4단계로서, 상기 탕약을 냉각한 후 100 내지 250 메쉬 여과포로 여과하여 여과액을 얻고, 여과액을 농축하여 1.2 내지 1.25 밀도의 진한 페이스트를 얻는 단계;As a fourth step, after cooling the medicament and filtered through a 100 to 250 mesh filter cloth to obtain a filtrate, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
제 5단계로서, 상기 진한 페이스트를 건조시킨 후, 건조된 결과물을 분쇄하고, 체로 걸러 표적 약물을 얻는 단계. As a fifth step, after drying the thick paste, the dried product is ground and sieved to obtain a target drug.
본 발명은 어깨 관절 주위염 치료를 위한 약물 및 그 제조방법을 개시한다. 본 발명에 따른 어깨 관절 주위염 치료 약물은 종래 약물들과 다른 구성을 갖고, 종래 약물들의 결함을 극복할 수 있다.The present invention discloses a drug for the treatment of periarthritis of the shoulder and a method of manufacturing the same. The shoulder arthritis therapeutic drug according to the present invention has a different configuration from the conventional drugs, and can overcome the deficiencies of the conventional drugs.
본 발명의 일 실시예는 금전초(Lysimachia christinae hance) 5 내지 18 중량부, 실고사리(Lygodium japonicum) 10 내지 25 중량부, 약모밀(Houttuynia cordata) 13 내지 20 중량부, 지렁이(Lumbricus) 12 내지 20 중량부 및 당귀(Angelica sinensis) 5 내지 15 중량부를 포함하는 어깨 관절 주위염 치료용 약물을 제공한다.One embodiment of the present invention is 5 to 18 parts by weight of Lysimachia christinae hance, 10 to 25 parts by weight of Lygodium japonicum, 13 to 20 parts by weight of Houttuynia cordata, 12 to 20 parts by weight of worms (Lumbricus) And Angelica sinensis provides a drug for treating shoulder periarthritis comprising 5 to 15 parts by weight.
또한, 상기 약물은 위령선(Radix Clematidis) 20 내지 30 중량부를 더 포함한다.In addition, the drug further comprises 20 to 30 parts by weight of the gastrointestinal (Radix Clematidis).
또한, 상기 약물은 상지(Ramulus Mori) 12 내지 18 중량부를 더 포함한다.In addition, the drug further comprises 12 to 18 parts by weight of the upper limb (Ramulus Mori).
상기 위령선과 상지는 일부 구체적인 예일 뿐이고 이로써 제한하고자 하는 의도는 아니며, 구기자(Wolfberry fruit), 돌외(Gynostemma pentaphyllum), 12 사원자(12 Semen astragali complanati), 속단(Radix dipsaci), 한련초(Herba eclipta), 여정자(Fructus ligustri lucidi) 등의 다른 재료도 가능하다. 다른 가능한 재료는 상세하게 기술되지 않을 것이다.The above lieutenant stomach and upper limbs are only some specific examples and are not intended to be limited thereto. Other materials are also possible, such as Fructus ligustri lucidi. Other possible materials will not be described in detail.
선택적으로, 본 발명의 일 실시예에서, 강황(Carcuma longa)과 달맞이꽃(Evening primrose)과 같은 혈액순환의 활력을 위한 재료가 추가될 수 있다.Optionally, in one embodiment of the present invention, materials for vitalization of blood circulation, such as Carcuma longa and Evening primrose, may be added.
또한, 본 발명의 일 실시예에서, 약리학적 효과를 향상시키기 위해 약물은 약모밀(Houttuynia cordata), 결명자(Semen cassiae), 목진피(Cortex fraxini), 고삼(Radix sophorae flavescentis), 감국(Flos chrysanthemi indici) 및 천심련(Andrographis paniculata) 등의 열을 제거하는 재료를 더 포함할 수 있다.In addition, in one embodiment of the present invention, the drug is to improve the pharmacological effects of the drug (Houttuynia cordata), Semen cassiae, Cortex fraxini, Radix sophorae flavescentis, Flos chrysanthemi indici And it may further include a material for removing heat, such as Andrographis paniculata.
또한, 약물은 수분초(Herba sedi) 및 계골초(Abrus herb)와 같은 습을 제거하고 이뇨를 촉진하는 재료를 더 포함할 수 있다.In addition, the drug may further include a material that removes moisture and promotes diuresis, such as Herba sedi and Abrus herb.
또한, 약물은 후추(Pepper)와 같이 내부를 따뜻하게 하는 물질을 더 포함할 수 있다.In addition, the drug may further include a material that warms the inside, such as pepper.
본 발명의 일 실시예에서, 약물의 제형은 필름 코팅 정제, 당 코팅 정제, 장용 코팅 정제, 분산성 정제, 캡슐제, 과립제, 탕약, 혼합물, 시럽, 약용 포도주, 주사제, 구강 용액 및 구강 현탁액 중 적어도 어느 하나이다.In one embodiment of the invention, the formulation of the drug is in film coated tablets, sugar coated tablets, enteric coated tablets, dispersible tablets, capsules, granules, decoctions, mixtures, syrups, medicinal wines, injectables, oral solutions and oral suspensions. At least one.
본 발명의 일 실시예에서, 선택적으로, 약물은 경구 투여형을 갖는다.In one embodiment of the invention, optionally, the drug has an oral dosage form.
본 발명의 일 실시예에서, 선택적으로, 상기 경구 투여형은 정제, 캡슐제, 알약, 주사제, 서방형 제제 및 조절된 방출 제제를 포함한다.In one embodiment of the invention, optionally, the oral dosage form comprises tablets, capsules, pills, injections, sustained release formulations and controlled release formulations.
본 발명의 일 실시예에 따른 약물 또는 이를 포함하는 약제 조성물은 장관, 비강, 경구 점막, 눈, 폐, 호흡기, 피부 및 직장 등을 통해 단위 제형으로 투여될 수 있고, 경구 투여, 정맥 내 주사, 근육 내 주사 및 피하 주사에 의해 투여될 수 있다.The drug according to an embodiment of the present invention or a pharmaceutical composition containing the same may be administered in unit dosage form through the intestine, nasal cavity, oral mucosa, eyes, lungs, respiratory system, skin and rectum, oral administration, intravenous injection, It can be administered by intramuscular injection and subcutaneous injection.
투여 제형은 액체 제형, 고체 제형 또는 반고체 제형일 수 있다. 액체 제형은 용액, 에멀젼, 서스펜션, 주입(물 주입, 분말 주입, 수혈을 포함), 점안제, 점비액, 로션 및 도찰제일 수 있고; 고체 제형은 정제(비코팅정제, 장용 코팅 정제, 구강정제, 분산성 정제, 씹을 수 있는 정제, 발포성 정제 및 경구 붕해형 정제를 포함), 캡슐(경질 캡슐, 연질 캡슐 및 장용 캡슐을 포함), 과립, 분말, 펠렛, 점적 환제, 좌약, 필름 제제, 페이스트, 에어로졸 및 스프레이 등의 제형일 수 있으며; 반고체 제형은 연고, 젤 및 페이스트 등의 제형일 수 있다. 약물의 제형은 바람직하게는 정제, 캡슐, 알약 및 주사제이다.Dosage formulations may be liquid, solid or semisolid formulations. Liquid formulations may be solutions, emulsions, suspensions, infusions (including water infusions, powder infusions, transfusions), eye drops, nasal drops, lotions, and stains; Solid dosage forms include tablets (including uncoated tablets, enteric coated tablets, oral tablets, dispersible tablets, chewable tablets, effervescent tablets and orally disintegrating tablets), capsules (including hard capsules, soft capsules and enteric capsules), Formulations such as granules, powders, pellets, drop pills, suppositories, film formulations, pastes, aerosols and sprays; Semi-solid formulations may be formulations such as ointments, gels and pastes. The formulation of the drug is preferably tablets, capsules, pills and injections.
본 발명의 일 실시예에 따른 약물은 통상적인 제조방법, 서방형 제제, 조절된 방출 제제, 표적화 제제 및 다양한 과립 투여 제제로 제조될 수 있다.Drugs according to one embodiment of the present invention may be prepared in conventional manufacturing methods, sustained release formulations, controlled release formulations, targeting formulations and various granule dosage formulations.
본 발명의 일 실시예에 따르면, 본 발명의 약물을 정제형으로 제조하기 위하여, 희석제, 결합제, 보습제, 붕해제, 윤활제 및 활택제와 같은 다양한 부형제를 사용할 수 있다. 희석제는 녹말, 덱스트린, 수크로스, 글루코스, 락토오스, 만니톨, 소르비톨, 자일리톨, 미정질의 셀룰로스, 황산칼슘, 인산수소칼슘 및 탄산칼슘 등일 수 있고; 보습제는 물, 에탄올 및 이소프로판올 등일 수 있으며; 결합제는 전분 펄프, 덱스트린, 시럽, 꿀, 글루코스 용액, 미결정 셀룰로오스, 아라비아 고무 펄프, 젤라틴 펄프, 소듐 카복시메틸 셀룰로오스 및 메틸 셀룰로오스일 수 있으며; 붕해제는 건조 전분, 미결정 셀룰로오스, 저치환 하이드록시프로필셀룰로오스일 수 있고; 윤활제와 활택제는 탈크, 실리카, 스테아레이트 및 액체 파라핀 등일 수 있다.According to one embodiment of the present invention, various excipients such as diluents, binders, moisturizers, disintegrants, lubricants and lubricants may be used to prepare the drug of the present invention in tablet form. Diluents can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate and the like; Humectants may be water, ethanol, isopropanol, and the like; The binder may be starch pulp, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic pulp, gelatin pulp, sodium carboxymethyl cellulose and methyl cellulose; Disintegrants can be dry starch, microcrystalline cellulose, low substituted hydroxypropylcellulose; Lubricants and lubricants may be talc, silica, stearate, liquid paraffin, and the like.
또한, 상기 약물은 코팅 정제일 수 있고, 예를 들어, 당 코팅 정제, 필름 코팅 정제 및 장용 코팅 정제 등일 수 있다.The drug may also be a coated tablet, for example, a sugar coated tablet, a film coated tablet, an enteric coated tablet, or the like.
상기 약물이 캡슐로 제조될 때, 활성 성분은 희석제, 결합제 및 붕해제를 첨가하여 과립이나 펠렛으로 제조될 수 있고, 이를 경질 캡슐 또는 연질 캡슐에 넣는다.When the drug is prepared in capsules, the active ingredient may be prepared in granules or pellets by the addition of diluents, binders and disintegrants, which are placed in hard capsules or soft capsules.
상기 약물이 주사제로 제조될 때, 용매는 물, 에탄올, 이소프로판올, 프로필렌글리콜 또는 이들의 혼합물로 제조될 수 있다. 또한, 적절한 양의 용해 보조제, 조용매, pH 조절제 및 삼투압 조절제가 첨가될 수 있다.When the drug is prepared as an injection, the solvent may be prepared from water, ethanol, isopropanol, propylene glycol or mixtures thereof. In addition, an appropriate amount of dissolution aid, cosolvent, pH adjuster and osmotic pressure adjuster may be added.
또한, 상기 약물은 착색제, 방부제, 향수, 교정제 및 다른 첨가제와 함께 첨가될 수 있다.The drug may also be added with colorants, preservatives, perfumes, correctors and other additives.
본 발명의 일 실시예에 따르면, 하기 단계를 포함하는 상기 약물의 제조방법이 제공된다.According to one embodiment of the invention, there is provided a method of preparing the drug comprising the following steps.
제 1단계로서, 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 무게 측정하는 단계;As a first step, 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of silcho, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworm, 5 to 15 parts by weight of donkey;
제 2단계로서, 상기 원료들을 분쇄하여 분말 혼합물을 얻는 단계;In a second step, grinding the raw materials to obtain a powder mixture;
제 3단계로서, 물에 상기 혼합물을 0.5 내지 1시간 동안 침지 후 결과물을 센 불에서 30분 동안 달여 탕약을 얻는 단계;In a third step, the mixture is immersed in water for 0.5 to 1 hour and then the resultant is decanted for 30 minutes on a high heat to obtain a decoction;
제 4단계로서, 상기 탕약을 냉각한 후 100 내지 250 메쉬 여과포로 여과하여 여과액을 얻고, 여과액을 농축하여 1.2 내지 1.25 밀도의 진한 페이스트를 얻는 단계;As a fourth step, after cooling the medicament and filtered through a 100 to 250 mesh filter cloth to obtain a filtrate, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
제 5단계로서, 상기 진한 페이스트를 건조시킨 후 건조된 결과물을 분쇄하고, 체로 걸러 표적 약물을 얻는 단계.As a fifth step, after drying the thick paste, the dried product is ground and sieved to obtain a target drug.
이하, 어깨 관절 주위염 치료를 위한 약물의 제조방법에 관한 몇가지 구체적인 예가 제시된다.Hereinafter, some specific examples of a method for preparing a drug for treating shoulder periarthritis are presented.
실시예Example 1 One
제 1단계로서, 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 무게 측정하는 단계;As a first step, 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of silcho, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworm, 5 to 15 parts by weight of donkey;
제 2단계로서, 상기 원료들을 각각 분쇄한 후 혼합하여 혼합물을 얻고, 물에 0.5 내지 1시간 동안 침지한 후 결과물을 50℃에서 30분동안 달여 탕약을 얻는 단계;In a second step, each of the raw materials are ground and mixed to obtain a mixture, and the resultant is immersed in water for 0.5 to 1 hour and then the resultant is decocted at 50 ° C. for 30 minutes to obtain decoction;
제 3단계로서, 5시간동안 상기 탕약을 냉각하고, 100 내지 150 메쉬의 여과포로 여과하여 여과액을 얻은 후, 여과액을 농축하여 1.2 내지 1.25 밀도의 두꺼운 페이스트를 얻는 단계;As a third step, cooling the medicament for 5 hours, filtered through a filter cloth of 100 to 150 mesh to obtain a filtrate, and then concentrated the filtrate to obtain a thick paste of 1.2 to 1.25 density;
제 4단계로서, 상기 두꺼운 페이스트를 건조하고, 건조된 결과물을 분쇄한 후 체로 걸러 표적 약물을 얻는 단계.As a fourth step, the thick paste is dried, and the dried product is pulverized and sieved to obtain a target drug.
실시예Example 2 2
제 1단계로서, 금전초 15 중량부, 실고사리 10 중량부, 약모밀 13 중량부, 지렁이 18 중량부, 위령선 20 중량부 및 당귀 12 중량부를 무게 측정하는 단계;As a first step, weighing 15 parts by weight of Geumchocho, 10 parts by weight of silgori, 13 parts by weight of weak hair, 18 parts by weight of earthworm, 20 parts by weight of the stomach line, and 12 parts by weight of Angelica;
제 2단계로서, 상기 원료들을 각각 고운 가루로 분쇄하고 100 메쉬의 체로 스크리닝하는 단계;As a second step, each of the raw materials are ground into fine powder and screened with a 100 mesh sieve;
제 3단계로서, 상기 스크리닝된 원료들을 30℃의 물로 40분 동안 달이고, 상온에서 12시간동안 계속 달여 탕약을 얻는 단계; As a third step, the screened raw materials to the moon for 30 minutes with water at 30 ℃, continued for 12 hours at room temperature to obtain a decoction;
제 4단계로서, 100 내지 250 메쉬의 여과포로 상기 탕약을 여과하여 여과액을 얻고, 여과액을 농축하여 두꺼운 페이스트를 얻는 단계;As a fourth step, filtering the medicament with a filter cloth of 100 to 250 mesh to obtain a filtrate, the filtrate is concentrated to obtain a thick paste;
제 5단계로서, 상기 두꺼운 페이스트를 건조하고, 건조된 결과물을 분쇄한 후, 체로 걸러 표적 약물을 얻는 단계.As a fifth step, drying the thick paste, pulverizing the dried resultant, and sieving to obtain the target drug.
실시예Example 3 3
제 1단계로서, 금전초 15 중량부, 실고사리 10 중량부, 약모밀 18 중량부, 지렁이 18 중량부, 위령선 30 중량부, 상지 15 중량부 및 당귀 12 중량부를 무게 측정하는 단계;As a first step, weighing 15 parts by weight of Geumjeoncho, 10 parts by weight of silgori, 18 parts by weight of wormwood, 18 parts by weight of earthworms, 30 parts by weight of the lieutenant stomach, 15 parts by weight of the upper limbs and 12 parts by weight of the donkey;
제 2단계로서, 상기 원료들을 혼합하여 혼합물을 얻고, 혼합물을 물에 침지시킨 후, 결과물을 달여 탕약을 얻는 단계;In a second step, mixing the raw materials to obtain a mixture, immersing the mixture in water, and then weighing the resultant to obtain a decoction;
제 3단계로서, 상기 탕약을 냉각하고 100 내지 250 메쉬의 여과포로 여과하여 여과액을 얻은 후, 여과액을 농축하여 1.2 내지 1.25 밀도의 두꺼운 페이스트를 얻는 단계;As a third step, after cooling the medicament and filtered through a filter cloth of 100 to 250 mesh to obtain a filtrate, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
제 4단계로서, 상기 두꺼운 페이스트를 3배량의 덱스트린과 혼합하여 연질 물질로 제조하고, 진동 과립기를 이용하여 낟알들로 만들어 과립을 얻는 단계;In a fourth step, the thick paste is mixed with three times the amount of dextrin to prepare a soft material, and is made into granules using a vibrating granulator to obtain granules;
제 5단계로서, 상기 낟알들을 30분동안 65℃에서 건조시키고 과립 스트레이트닝을 수행한 후, 스크리닝 하여 작은 낟알들을 제거하고, 포장하는 단계.As a fifth step, the granules were dried at 65 ° C. for 30 minutes, granulated straightening was performed, and then screened to remove small granules and packaged.
실시예Example 4 4
제 1단계로서, 금전초 15 중량부, 실고사리 10 중량부, 약모밀 18 중량부, 지렁이 18 중량부, 위령선 30 중량부, 상지 15 중량부 및 당귀 12 중량부를 무게 측정하는 단계;As a first step, weighing 15 parts by weight of Geumjeoncho, 10 parts by weight of silgori, 18 parts by weight of wormwood, 18 parts by weight of earthworms, 30 parts by weight of the lieutenant stomach, 15 parts by weight of the upper limbs and 12 parts by weight of Angelica
제 2단계로서, 상기 원료들을 혼합하여 혼합물을 얻고, 혼합물을 물에 침지시킨 후, 결과물을 달여 탕약을 얻는 단계;In a second step, mixing the raw materials to obtain a mixture, immersing the mixture in water, and then weighing the resultant to obtain a decoction;
제 3단계로서, 상기 탕약을 냉각하고 100 내지 250 메쉬의 여과포로 여과하여 여과액을 얻은 후, 여과액을 농축하여 1.2 내지 1.25 밀도의 두꺼운 페이스트를 얻는 단계;As a third step, after cooling the medicament and filtered through a filter cloth of 100 to 250 mesh to obtain a filtrate, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
제 4단계로서, 상기 두꺼운 페이스트를 3배량의 덱스트린과 혼합하여 연질 물질로 제조하고, 진동 과립기를 이용하여 낟알들로 만들어 과립을 얻는 단계;In a fourth step, the thick paste is mixed with three times the amount of dextrin to prepare a soft material, and is made into granules using a vibrating granulator to obtain granules;
제 5단계로서, 상기 낟알들을 30분동안 65℃에서 건조시키고 과립 스트레이트닝을 수행한 후, 단식 정제기로 정제화하여 0.3g 중량의 정제를 얻는 단계.As a fifth step, the granules were dried at 65 ° C. for 30 minutes and granulated straightening, followed by tableting with a single-stage tablet to obtain 0.3 g of tablets.
본 발명에 따른 어깨 관절 주위염 치료 약물은 종래 약물들과 다른 구성을 갖고, 종래 약물들의 결함을 극복할 수 있다.The shoulder arthritis therapeutic drug according to the present invention has a different configuration from the conventional drugs, and can overcome the deficiencies of the conventional drugs.
Claims (5)
Drugs for the treatment of periarthritis of the shoulder, including 5 to 18 parts by weight, 10 to 25 parts by weight of fern, 13 to 20 parts by weight, worms 12 to 20 parts by weight, and 5 to 15 parts by weight of Angelica
상기 약물은 위령선 20 내지 30 중량부를 더 포함하는 어깨 관절 주위염 치료용 약물
The method according to claim 1,
The drug is a drug for the treatment of periarthritis of the shoulder further comprising 20 to 30 parts by weight gastric gland
상기 약물은 상지 12 내지 18 중량부를 더 포함하는 어깨 관절 주위염 치료용 약물
The method according to claim 1,
The drug is a drug for the treatment of periarthritis of the shoulder further comprising 12 to 18 parts by weight of the upper limbs
상기 약물은 필름 코팅 정제, 당 코팅 정제, 장용 코팅 정제, 분산성 정제, 캡슐제, 과립제, 탕약제, 혼합물, 시럽, 약용 포도주, 주사제, 경구용 용액 및 경구용 현탁액 중 적어도 어느 하나의 제형인 어깨 관절 주위염 치료용 약물
The method according to claim 1,
The drug may be in the form of at least one of film-coated tablets, sugar-coated tablets, enteric coated tablets, dispersible tablets, capsules, granules, decoctions, mixtures, syrups, medicinal wines, injectables, oral solutions and oral suspensions. Drugs for the treatment of periarthritis of the shoulder
제 1단계로서, 금전초 5 내지 18 중량부, 실고사리 10 내지 25 중량부, 약모밀 13 내지 20 중량부, 지렁이 12 내지 20 중량부, 당귀 5 내지 15 중량부를 무게 측정하는 단계;
제 2단계로서, 상기 원료들을 분쇄하여 분말 혼합물을 얻는 단계;
제 3단계로서, 물에 상기 혼합물을 0.5 내지 1시간 동안 침지 후 센 불에서 30분동안 결과물을 달여 탕약을 얻는 단계;
제 4단계로서, 상기 탕약을 냉각한 후 100 내지 250 메쉬 여과포로 여과액을 얻고, 여과액을 농축하여 1.2 내지 1.25 밀도의 진한 페이스트를 얻는 단계;
제 5단계로서, 상기 진한 페이스트를 건조시킨 후 건조된 결과물을 분쇄하고, 체로 걸러 표적 약물을 얻는 단계. A method of preparing a medicament according to any one of claims 1 to 4, comprising the following steps:
As a first step, 5 to 18 parts by weight of Geumchocho, 10 to 25 parts by weight of silcho, 13 to 20 parts by weight of weak hair, 12 to 20 parts by weight of earthworm, 5 to 15 parts by weight of donkey;
In a second step, grinding the raw materials to obtain a powder mixture;
In a third step, the mixture is immersed in water for 0.5 to 1 hour and then the resultant is weighed for 30 minutes on a high heat to obtain a medicinal solution;
As a fourth step, after the coolant is cooled to obtain a filtrate with a 100 to 250 mesh filter cloth, the filtrate is concentrated to obtain a thick paste of 1.2 to 1.25 density;
As a fifth step, after drying the thick paste, the dried product is ground and sieved to obtain a target drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180065567A KR20190139053A (en) | 2018-06-07 | 2018-06-07 | A drug for treating shoulder periarthritis and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180065567A KR20190139053A (en) | 2018-06-07 | 2018-06-07 | A drug for treating shoulder periarthritis and its preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190139053A true KR20190139053A (en) | 2019-12-17 |
Family
ID=69056607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180065567A KR20190139053A (en) | 2018-06-07 | 2018-06-07 | A drug for treating shoulder periarthritis and its preparation method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190139053A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230050735A (en) | 2021-10-08 | 2023-04-17 | 최지연 | Ear tips detachable low-latency wireless earphones |
-
2018
- 2018-06-07 KR KR1020180065567A patent/KR20190139053A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230050735A (en) | 2021-10-08 | 2023-04-17 | 최지연 | Ear tips detachable low-latency wireless earphones |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20190139053A (en) | A drug for treating shoulder periarthritis and its preparation method | |
KR20190122982A (en) | A drug for treating shoulder periarthritis and its preparation method | |
KR20190115223A (en) | A drug for treating pharyngitis and its preparation method | |
KR20190107308A (en) | A drug for treating gout and its preparation method | |
KR20190134213A (en) | A drug for treating gastrohelcosis and its preparation method | |
KR20190115789A (en) | A drug for treating osteoporosis and its preparation method | |
KR20230116311A (en) | Shoulder periarthritis used composition | |
KR20190107845A (en) | A drug for treating shoulder periarthritis and its preparation method | |
KR20190132825A (en) | A drug for treating shoulder periarthritis and its preparation method | |
KR20190112486A (en) | A drug for treating shoulder periarthritis and its preparation method | |
KR20190139019A (en) | A drug for treating pharyngitis and its preparation method | |
KR20190117893A (en) | A drug for treating osteoporosis and its preparation method | |
KR20190127033A (en) | A drug for treating osteoporosis and its preparation method | |
KR20190134210A (en) | A drug for treating osteoporosis and its preparation method | |
KR20230113060A (en) | A drug for treating osteoporosis and its preparation method | |
KR20190126571A (en) | A Drug for Treating Osteoporosis and its Preparation Method | |
KR20190105834A (en) | A drug for treating gout and its preparation method | |
KR20190121002A (en) | A drug for treating pharyngitis and its preparation method | |
KR20190132887A (en) | A drug for treating pharyngitis and its preparation method | |
KR20190107871A (en) | A drug for treating gout and its prepration method | |
KR20230115138A (en) | A drug for treating pharyngitis and its preparation method | |
KR20190142041A (en) | A drug for treating gastrohelcosis and its preparation method | |
KR20190134182A (en) | A drug for treating osteoporosis and its preparation method | |
KR20190103892A (en) | A drug for treating gout and its preparation method | |
KR20190093955A (en) | A drug for treating gout and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |